Mar 14, 2019ATXA attends BioCapital EuropeATXA Therapeutics is attending BioCapital Europe in Amterdam today. #Lifesciences #investment
ATXA Therapeutics Publishes Results of Phase 1 First-in-Human Study Evaluating the Safety & Tolerability of NTP42 in Healthy Volunteers
